A1010
Arsenic(III) oxide
ReagentPlus®, ≥99.0%
Synonym(s):
Arsenic trioxide, Arsenous acid
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
As2O3
CAS Number:
Molecular Weight:
197.84
EC Number:
MDL number:
UNSPSC Code:
12352300
PubChem Substance ID:
NACRES:
NA.55
Recommended Products
vapor pressure
0 hPa ( 66 °C)
Quality Level
product line
ReagentPlus®
Assay
≥99.0%
form
powder
storage temp.
room temp
SMILES string
O=[As]O[As]=O
InChI
1S/As2O3/c3-1-5-2-4
InChI key
IKWTVSLWAPBBKU-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
Arsenic(III) oxide, also known as arsenic trioxide, is an amphoteric oxide that serves as a raw material for the synthesis of several arsenic-based compounds. It is utilized to decolorize glasses and enamels. Its efficacy in treating in acute promyelocytic leukaemia (APL) has been investigated.
Application
Arsenic(III) oxide was used in a study detailing the effect of arsenic trioxide in combination with γ-irradiation to elucidate the hemoglobin (Hb).
Biochem/physiol Actions
Very potent agent against acute promyelocytic leukemia (APL). Causes skin, lung and bladder cancer.
Legal Information
ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Eye Dam. 1 - Skin Corr. 1B - STOT RE 1
Storage Class Code
6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Combined effect of arsenic trioxide and radiation on physical properties of hemoglobin biopolymer.
Saad-El-Din AA, et al.
Journal of Radiation Research and Applied Sciences, 7(2), 411-416 (2014)
Wilson H Miller et al.
Cancer research, 62(14), 3893-3903 (2002-07-19)
Arsenic trioxide has shown substantial efficacy in treating both newly diagnosed and relapsed patients with acute promyelocytic leukemia (APL). As a single agent, it induces complete remissions, causing few adverse effects and only minimal myelosuppression. These successes have prompted investigations
E Lengfelder et al.
Leukemia, 26(3), 433-442 (2011-09-10)
Arsenic trioxide (ATO) is presently the most active single agent in the treatment of acute promyelocytic leukemia (APL). This review provides insights into the mode of action and the pharmacological properties of ATO, and summarizes the most relevant results of
Dikshith TSS
Handbook of Chemicals and Safety, 92-92 (1992)
Z X Shen et al.
Blood, 89(9), 3354-3360 (1997-05-01)
The therapeutic effect of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) was evaluated among 15 APL patients at relapse after all-trans retinoic acid (ATRA) induced and chemotherapy maintained complete remission (CR). As2O3 was administered intravenously at
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service